Mounjaro Triumphs Over Trulicity: A New Era in Diabetes Care

Eli Lilly's diabetes drug Mounjaro demonstrated superior efficacy to its predecessor Trulicity in reducing heart attack and stroke risks in a major trial. This advancement positions Mounjaro as a leading treatment option, with promising implications for FDA approval and expanded use against other diseases.

Eli Lilly announced a significant victory for its newer diabetes drug, Mounjaro, which outperformed Trulicity in mitigating heart attack and stroke risks, a groundbreaking trial revealed.

The study involved over 13,000 patients with type 2 diabetes and high cardiovascular risk, showcasing an 8% greater risk reduction for Mounjaro in major cardiac events than Trulicity, alongside a notable 16% lower mortality risk. Despite both drugs sharing similar safety profiles, more participants discontinued Mounjaro due to gastrointestinal side effects.

Lilly aims to submit these findings for FDA approval, potentially expanding the therapeutic reach of Mounjaro while engaging in competitive dynamics with Novo Nordisk's GLP-1 drugs. This move also highlights the ongoing race to establish these medications as leading treatments for various major diseases, beyond diabetes.

(With inputs from agencies.)